AIMS: The aim of the study was to assess the clinical efficacy of antazoline, a first-generation anti-histaminic agent, in the rapid conversion of paroxysmal non-valvular atrial fibrillation (AF) to sinus rhythm in patients without heart failure. METHODS AND RESULTS: This study was a single center, randomized, double blind, placebo-controlled, superiority clinical trial. We enrolled patients with an AF episode lasting less than 43 h, in stable cardiopulmonary condition. Subjects who fulfilled the selection criteria were randomly assigned to receive intravenously either a placebo or up to 250 mg of antazoline. The primary end point was the conversion of AF to sinus rhythm confirmed in electrocardiogram (ECG). We enrolled 74 patients: 36 (48.6%) in the antazoline group and 38 (51.4%) in the control group. The mean age was 68 ± 12 years (range 31-90 years), 39 (53.3%) patients were male. The successful conversion of AF to sinus rhythm during the observation period was achieved in 26 (72.2%) patients treated with antazoline and 4 (10.5%) in the control group: RR 6.86 (95% CI: 2.66-17.72, P < 0.0001). Median time to conversion was 16.0 min in antazoline and 72.5 min in the control group (P = 0.0246). There were no cases of atrial tachycardia/flutter in the antazoline group. CONCLUSION: Intravenous antazoline was effective and safe in the rapid conversion of non-valvular paroxysmal atrial fibrillation to sinus rhythm in patients without heart failure. Clinical Trial Registration number: NCT01527279. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The aim of the study was to assess the clinical efficacy of antazoline, a first-generation anti-histaminic agent, in the rapid conversion of paroxysmal non-valvular atrial fibrillation (AF) to sinus rhythm in patients without heart failure. METHODS AND RESULTS: This study was a single center, randomized, double blind, placebo-controlled, superiority clinical trial. We enrolled patients with an AF episode lasting less than 43 h, in stable cardiopulmonary condition. Subjects who fulfilled the selection criteria were randomly assigned to receive intravenously either a placebo or up to 250 mg of antazoline. The primary end point was the conversion of AF to sinus rhythm confirmed in electrocardiogram (ECG). We enrolled 74 patients: 36 (48.6%) in the antazoline group and 38 (51.4%) in the control group. The mean age was 68 ± 12 years (range 31-90 years), 39 (53.3%) patients were male. The successful conversion of AF to sinus rhythm during the observation period was achieved in 26 (72.2%) patients treated with antazoline and 4 (10.5%) in the control group: RR 6.86 (95% CI: 2.66-17.72, P < 0.0001). Median time to conversion was 16.0 min in antazoline and 72.5 min in the control group (P = 0.0246). There were no cases of atrial tachycardia/flutter in the antazoline group. CONCLUSION: Intravenous antazoline was effective and safe in the rapid conversion of non-valvular paroxysmal atrial fibrillation to sinus rhythm in patients without heart failure. Clinical Trial Registration number: NCT01527279. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Michal M Farkowski; Aleksander Maciag; Ilona Kowalik; Marek Konka; Hanna Szwed; Mariusz Pytkowski Journal: Br J Clin Pharmacol Date: 2019-05-23 Impact factor: 4.335
Authors: Gerrit Frommeyer; André Mittelstedt; Julian Wolfes; Christian Ellermann; Simon Kochhäuser; Patrick Leitz; Dirk G Dechering; Lars Eckardt Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2017-08-06 Impact factor: 3.000
Authors: Bartłomiej Jacek Bińkowski; Marcin Makowski; Paweł Kubiński; Andrzej Lubiński Journal: Cardiovasc Drugs Ther Date: 2018-04 Impact factor: 3.727
Authors: Joanna Giebułtowicz; Natalia Korytowska; Monika Sobiech; Sebastian Polak; Barbara Wiśniowska; Roman Piotrowski; Piotr Kułakowski; Piotr Luliński Journal: Int J Mol Sci Date: 2021-04-01 Impact factor: 5.923
Authors: Beata Ceynowa-Sielawko; Maciej T Wybraniec; Aleksandra Topp-Zielińska; Aleksander Maciąg; Dawid Miśkowiec; Paweł Balsam; Maciej Wójcik; Wojciech Wróbel; Michał M Farkowski; Edyta Ćwiek-Rębowska; Krzysztof Ozierański; Robert Błaszczyk; Karolina Bula; Tomasz Dembowski; Michał Peller; Bartosz Krzowski; Wojciech Wańha; Marek Koziński; Jarosław D Kasprzak; Hanna Szwed; Katarzyna Mizia-Stec; Marek Szołkiewicz Journal: Int J Environ Res Public Health Date: 2022-04-17 Impact factor: 3.390
Authors: Maciej T Wybraniec; Wojciech Wróbel; Katarzyna Wilkosz; Karolina Wrona; Karolina Bula; Katarzyna Mizia-Stec Journal: J Am Heart Assoc Date: 2018-10-16 Impact factor: 5.501
Authors: Barbara Wiśniowska; Joanna Giebułtowicz; Roman Piotrowski; Piotr Kułakowski; Sebastian Polak Journal: Pharmaceuticals (Basel) Date: 2022-03-20